Express Mail Label No. EL 960328433 US
Docket No. JAB 1702 US WO

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: LACRAMPE, Jean Fernand Armand, et al.

Serial No. : Not Assigned Art Unit: TBA

Filed : Herewith Examiner: TBA

For : 3-Furanyl Analogs Of Toxoflavine As Kinase

Inhibitors

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

#### INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

Express Mail Label No. EL 960328433 US Docket No. JAB 1702 US WO

$\boxtimes$	In acc	cordance with §1.97(b), since this Information
Disclosure	State	ment is being filed either within three months
of the fil	ing da	te of the above-identified national application
(other tha	n a co	ntinued prosecution application under
§1.53(d)),	withi	n three months of the date of entry into the
national s	tage c	f the above identified application as set forth
in §1.491,	or be	fore the mailing date of a first Office Action
on the mer	its of	the above-identified application, or before
the mailin	g date	of a first Office Action after the filing of a
request fo	r cont	inued examination under §1.114, no additional
fee is req	uired.	
	_	1
		cordance with §1.129(a), this Information
Disclosure	State	ment is being filed in connection with [] the
first or [	]secon	d After Final Submission, therefore:
		Statement in Accordance with §1.97(e)
	(	(attached); or
•	F	Please charge Deposit Account No. 10-
	C	750/ / the fee of \$180.00 as set forth
	į	n §1.17(p).
	In acc	cordance with §1.97(c), this Information
Disalesumo		
		ment is being filed after the period set forth
		e but before the mailing date of either a Final
		113 or a Notice of Allowance under §1.311, or
		therwise closes prosecution and that it is
accompanie	ed by c	ne of:
		Statement in Accordance with §1.97(e)
	1	(attached); or
		Please charge Deposit Account No. 10-
	(	750/ / the fee of \$180.00 as set forth
	i	n §1.17(p).

Express Mail Label No. EL 960328433 US
Docket No. JAB 1702 US WO

In accordance with §1.97(d), this Information
Disclosure Statement is being filed after the mailing date of
either a Final Action under §1.113 or a Notice of Allowance
under §1.311 but before the payment of the Issue Fee.
Applicant(s) hereby petition(s) for consideration of this
Information Disclosure Statement. Included are: Statement in
Accordance with §1.97(e) as set forth below and the fee of
\$180.00 as set forth in §1.17(p).
Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.
Copies of references listed on the attached Form PTO
1449 are enclosed herewith EXCEPT THAT:
In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.
☐ Copies of only foreign patent documents and non-
patent literature are enclosed in accordance with 37 CFR 1.98
(a)(2). (The U.S. patents and each U.S. patent application
publication listed on the attached Form PTO-1449 are not
enclosed because this U.S. patent application was filed after

June 30, 2003 or this international application has entered the

Express Mail Label No. EL 960328433 US
Docket No. JAB 1702 US WO

national stage under 35 USC §371 after June 30, 2003 (see USPTO waiver of requirement under 37 CFR 1.98 (a)(2)(i).

$oxed{\boxtimes}$ There are no listed references which are not in the
English language.
·
The relevance of those listed references which are
not in the English language is as follows:
Attached are copies of search report(s) from
corresponding patent application(s), which are listed on the
attached Submission Under MPEP 609 D.
Attached are the following non-published pending
patent applications which may be deemed relevant, which are

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/-JAB1702PCT-US/AGK. This form is submitted in triplicate.

listed on the attached Submission Under MPEP 609 D.

Respectfully submitted,

Alana Kiegman

Reg. No. 41,747

Attorney for Applicants

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (732) 524-1495 DATED: January 7, 2005

JT12 Rec'd PCT/PTO, 0 7 JAN 2005 use through 10/31/2002, OMB 0651-00

ce: U.S. DEPARTMENT OF COMMERCE ct of 1995, no persons are required to re-Under the Paperwork Red

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of 2

U.S. Patent Document

ns are required to resp	pond to a collection of information less it of	displays a valid OMB control number.		
	Application Number	Not Assigned		
	Filing Date			
SURE	First Named Inventor	Lacrampe, Jean Fernand Armand TBA		
CANT				
CANI	Group Art Unit			
	Examiner Name	TBA		
	Attorney Docket Number	JAB1702US -WO (PCT)		
U.S. PATENT DOCUMENTS				

ode² wn)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
	Jacques H. Bertoglio-Matte	02-04-1986	

Kind Coo Examiner Initials (if know No.1 Number 4,568,649

**FOREIGN PATENT DOCUMENTS** 

	Cite No.1	Foreign Patent Document		nent	Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	
Examiner Initials		Office <sup>3</sup>	Number <sup>4</sup>	KindCode <sup>5</sup>	Applicant of Cited Document	mm-dd-yyyy	passages or relevant figures appear	T <sup>©</sup>
		JP	09-255681	A2	Taisho Pharmaceut CO LTD	09-30-1997		
		GB	2039883	Α .	Vsesojuzny Nauchno-Issledovatelsky Institut Antibiotikov, Nagatinskaya ulitsa, 3-a, Moscow	08-20-1980		
		wo	02/20525	A2	Institute Of Molecular and Cell Biology	03-14-2002		
		wo	02/20525	А3	Institute Of Molecular and Cell Biology	03-14-2002		
		wo	02/02552	A1	Glaxo Group Limited	01-10-2002		
Examiner Signature					Date Conside	ered		l

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents, 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

1)T12 Rec'd PCT/PTO 0 7 JAN 2005

Appr U.S. Patent and Trade Under the Paperwork Red ct of 1995, no persons are required to respond

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of 2

to a conection of information less it displays	s a valid OMB control number.
Application Number	Not Assigned
Filing Date	
First Named Inventor	Lacrampe, Jean Fernand Armand
Group Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	JAB1702US-WO

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item  (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),  publisher, city and/or country where published	T²
		MEIJER L., et al., "Chemical Inhibitors of Cyclin-Dependent Kinases", Progress in Cell Cycle Research, Vol. 1, 351-363, 1995	
		KAUR, et al., "Growth Inhibition With Reversible Cell Cycle Arrest of Carcinoma Cells by Flavone L86-8275", J. Natl. Cancer Inst., Vol. 84(22), 1736-1740, 1992	
		SEDLACEK, et al., "Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy", Int. J. Oncol, Vol 9:1143-1168, 1996	
		VESELY, et al., "Inhibition of cyclin-dependent kinases by purine analogues", Eur. J. Biochem, 224, 771-786, 1994	
		GENNARO, et al., "Remington's Pharmaceutical Sciences", 18 <sup>th</sup> edition, Mack Publishing Company, 1990 book cover & table of contents	
		NAGAMATSU, et al., "General syntheses of 1-alkyltoxoflavin and 8-alkylfervenulin derivatives of biological significance by the regioselective alkylation of reumycin derivatives and the rates of transalkylation from 1-alkyltoxoflavins into nucleophiles", J. Chem. Soc., Perkin Trans. 1, 130-137, 2001	
		NAGAMATSU, et al., "Syntheses of 3-Substituted 1-Methyl-6-phenylpyrimido[5,4-e]-1,2,4-triazine-5,7(1H,6H)-diones (6- Phenyl Analogs of Toxoflavin) and Their 4-Oxides, and Evaluation of Antimicrobial Activity of Toxoflavins and Their Analogs", Chem. Pharm. Bull 41(2) 362-368, 1993	
		WILEY & SONS, INC., "Fused Pyrimidines Miscellaneous Fused Pyrimidines", Heterocyclic Compounds, Vol. 24 (part 4) p. 261-304	
			_

Examiner	Date
Signature	Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA

22313-1450.

t Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

10/520641

OT12 Rec'd PCT/PTO 0 7 JAN 2005

### SUBMISSION UNDER MPEP 609 D

Page 1 of 1

Application Number	Not Assigned
Filing Date	Herewith
First Named Inventor	Lacrampe, Jean Fernand Armand
Group Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	JAB1702US-WO

Examiner Initials No.1 Name of Patentee or Applicant of Cited Document Of Cited Document Number (if known) Pages, Columns, Lines, where relevant passages or relevant figures appear

## FOREIGN PATENT DOCUMENTS Foreign Patent Document Pages, Columns, Lines, where relevant passages Name of Patentee or Examiner Cite or relevant figures Applicant of Cited Document Number<sup>4</sup> KindCode<sup>5</sup> Office<sup>3</sup> appear No.1 OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), Examiner Cite No.1 T<sup>2</sup> title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published Initials\* International Search Report mailed October 23, 2003 for PCT/EP03/50293

Examiner	Da	e	
Signature	Co	nsidered	